Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
5.01
-0.12 (-2.34%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
It also develops TGF-β, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Inventiva S.A.
| Country | France |
| Founded | 2011 |
| IPO Date | Jul 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 77 |
| CEO | Andrew Obenshain |
Contact Details
Address: 50 rue de Dijon Daix, 21121 France | |
| Phone | 33 3 80 44 75 00 |
| Website | inventivapharma.com |
Stock Details
| Ticker Symbol | IVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $14.40 |
| CIK Code | 0001756594 |
| CUSIP Number | 46124U107 |
| ISIN Number | US46124U1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andrew Obenshain | Chief Executive Officer |
| Dr. Pierre Broqua Ph.D. | Co-Founder |
| Jean Volatier | Deputy GM and Chief Financial Officer |
| Dr. Martine Zimmermann Pharm.D. | Executive Vice President of Regulatory Affairs and Quality Assurance and Head of Regulatory Affairs |
| Jason A. Campagna M.D., Ph.D. | President of Research and Development and Chief Medical Officer |
| Eric Duranson L.L.M. | General Counsel |
| Nathalie Harroy | Head of Human Resources |
| Pascaline Clerc Ph.D. | Executive Vice President of External and Corporate Affairs |
| Nazira Amra M.D. | Chief Commercial Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | 6-K | Report of foreign issuer |
| Apr 8, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Apr 1, 2026 | SCHEDULE 13D/A | Filing |
| Mar 30, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | 6-K | Report of foreign issuer |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Jan 30, 2026 | SCHEDULE 13G | Filing |